The FDA has approved the intravenous antibiotic Emblaveo for adults with complicated intra-abdominal infections who have limited treatment options.
This rate is higher than observed in children treated with a beta-lactamase resistant agent, although the associated risk estimate reached statistical significance (pooled OR: 2.39 [95% CI ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback